Summary & Overview
CPT 90384: Rho(D) (Rhesus D) Immune Globulin, Full Dose
CPT code 90384 identifies a full dose of human Rho(D) immune globulin used to prevent Rhesus disease (hemolytic disease of the newborn) by providing passive anti-Rho(D) antibodies. This prophylactic biologic is clinically important in obstetrics to reduce alloimmunization after potential fetal-maternal blood exposure. Nationally, appropriate use of 90384 affects maternal and neonatal outcomes and drives utilization in outpatient obstetric and infusion settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service settings for 90384, plus benchmarking and payer policy considerations where data is available. The publication highlights coding and billing implications, typical sites of service, and what to expect from major payers regarding coverage patterns. Data not available in the input is noted where relevant.
Billing Code Overview
CPT code 90384 describes a full dose of human Rho(D) immune globulin derived from plasma of immunized healthy donors. Rho(D) (Rhesus D) immune globulin is a preparation of immunoglobulin used to provide passive immunity and to prevent Rhesus disease (hemolytic disease of the newborn) by neutralizing Rhesus D antigen exposure in at-risk individuals.
Service Type: Immune globulin administration for Rho(D) prophylaxis
Typical Site of Service: Outpatient clinics, obstetrics/gynecology clinics, hospital outpatient departments, and infusion centers
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A 28-year-old Rh-negative pregnant woman presents at 28 weeks' gestation after routine prenatal antibody screening is negative for anti-D but reports a recent episode of abdominal trauma. The obstetric clinician documents risk of fetomaternal hemorrhage and orders human Rho(D) immune globulin prophylaxis to prevent maternal sensitization to the rhesus D antigen. The patient receives a full-dose intramuscular administration of 90384 (Rho(D) immune globulin) in the outpatient obstetrics clinic. The clinical workflow includes informed consent, verification of maternal Rh-negative status and current antibody screen, assessment for any prior Rho(D) immune globulin administration or transfusion history, preparation and administration of the medication, post-injection observation for anaphylaxis or local reaction, and documentation of lot number, dose, administration site, and the indication in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management (E/M) service by the same physician on the same day of the procedure | Use when an E/M visit is performed and documented on the same day as 90384 for a separate reason (e.g., assessment after trauma prompting Rho(D) administration). |